Open Label Arimidex in Gynecomastia

Study identifier:D5394C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-Label Pharmacokinetic and Pharmacodynamic Study of Anastrozole (Arimidex™) Used to Treat Pubertal Boys with Gynecomastia of Recent Onset

Medical condition

Gynecomastia

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

Male

Actual Enrollment

35

Study type

Interventional

Age

11 Years - 18 Years

Date

Study Start Date: 01 Jun 2005
Primary Completion Date: 01 Nov 2006
Study Completion Date: 01 Nov 2006

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria